BrainsWay Announces Published Review Results Highlighting Potential Of Deep TMS To Treat Parkinson's Disease
Portfolio Pulse from Benzinga Newsdesk
BrainsWay Ltd. (NASDAQ: BWAY) announced results from a review article published in Frontiers of Human Neuroscience, highlighting the potential of Deep Transcranial Magnetic Stimulation (Deep TMS) to treat Parkinson's Disease (PD). The review, which summarized data from six studies involving 220 patients, showed clinically meaningful improvements in motor and non-motor symptoms. The company emphasized the need for further research, noting that Deep TMS is not yet FDA cleared for treating PD.
April 04, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BrainsWay's announcement of promising Deep TMS results for Parkinson's Disease could positively impact investor sentiment, despite the treatment not being FDA cleared yet.
The publication of positive review results for Deep TMS in treating Parkinson's Disease highlights BrainsWay's potential in expanding its treatment portfolio. Although the treatment is not FDA cleared for PD, the positive data could increase investor optimism about the company's future prospects and research capabilities. However, the impact is moderated by the need for further research and regulatory approvals.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90